Skip to main content

Day: August 19, 2020

GTT Receives NYSE Notice Regarding Delayed Form 10-Q Filing

MCLEAN, Va., Aug. 19, 2020 (GLOBE NEWSWIRE) — GTT Communications, Inc. (NYSE: GTT) (the “Company”), a leading global cloud networking provider to multinational clients, today announced that it received a notice from the New York Stock Exchange (the “NYSE”) indicating that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”). The notice has no immediate effect on the listing of the Company’s stock on the NYSE.The NYSE informed the Company that, under the NYSE’s rules, the Company can regain compliance with the NYSE’s continued listing requirements by filing the Form 10-Q with the SEC at any time prior to February...

Continue reading

PolyPid Ltd. Provides Corporate Update and Reports Second Quarter 2020 Financial Results

Initiated Phase 3 SHIELD I Trial for D-PLEX100 in Abdominal Surgery and Received Fast Track Designation for D-PLEX100 from FDAPresented Positive Phase 2 Results of D-PLEX100 for Prevention of Surgical Site Infections in Abdominal Surgery at ASCRS MeetingCompleted Initial Public Offering in U.S., Raising Net Proceeds of $62.8 MillionConference Call scheduled for Wednesday, August 19 at 8:30 AM Eastern TimePETAH TIKVA, Israel, Aug. 19, 2020 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today provided a corporate update and reported financial results for the three and six months ended June 30, 2020.Recent Corporate Highlights:Enrolled and randomized the first...

Continue reading

QIWI Announces Second Quarter 2020 Financial Results

Second Quarter Total Net Revenue Increases 23% to RUB 6,839 Million and Adjusted Net Profit Increases 40% to RUB 2,756 Million or RUB 44.19 per diluted shareQIWI upgrades 2020 GuidanceBoard of Directors Approves Dividends of 33 cents per shareNICOSIA, Cyprus, Aug. 19, 2020 (GLOBE NEWSWIRE) — QIWI plc (NASDAQ: QIWI) (MOEX: QIWI) (“QIWI” or the “Company”) today announced results for the second quarter ended June 30, 2020.Second Quarter 2020 Operating and Financial Highlights

Continue reading

Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Parkinson’s Disease

NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that the Shake It Up Foundation for Parkinson’s Research and its international partners has committed to invest into Anavex up to 50% of the costs of a disease modifying clinical study to develop ANAVEX®2-73 (blarcamesine) for the disease modifying treatment of Parkinson’s disease.“Shake It Up is proud and excited to support research like this that may create opportunities for breakthroughs that could be a game-changer for people with Parkinson’s,”...

Continue reading

Troilus Receives Environmental Approval to Commence Dewatering of Z87 and J4 Pits

TORONTO, Aug. 19, 2020 (GLOBE NEWSWIRE) — Troilus Gold Corp. (TSX: TLG; OTCQB: CHXMF) (“Troilus” or the “Company”) is pleased to announce that it has received a Certificate of Authorization from the Ministère de l’Environnement et de la Lutte contre les changements climatiques (“MELCC”) under Section 115.8 of the Environment Quality Act (Chapter Q02) to proceed with the dewatering of the Z87 and J4 pits (together, the “Pits”). To obtain approval for the dewatering of the Pits, Troilus submitted an Environmental Impact Assessment (“EIA”) on November 19, 2019, which was subject to a thorough review by MELCC.  Troilus also engaged in community consultations with impacted families on the Troilus property and the local communities of Mistissini and Chibougamau to keep them informed of the dewatering proposal and integrate the feedback...

Continue reading

Troilus reçoit l’autorisation environnementale pour commencer l’assèchement des fosses Z87 et J4

TORONTO, 19 août 2020 (GLOBE NEWSWIRE) — Troilus Gold Corp. (TSX : TLG; OTCQB : CHXMF) (« Troilus » ou la « Société ») est heureuse d’annoncer qu’elle a reçu un certificat d’autorisation du Ministère de l’Environnement et de la Lutte contre les changements climatiques (« MELCC ») en vertu du paragraphe 115.8 de la Loi sur la qualité de l’environnement (chapitre Q-2) pour procéder à l’assèchement des fosses Z87 et J4 (ensemble, les « fosses »). Pour obtenir l’approbation de l’assèchement des fosses, Troilus a soumis une étude d’impact environnemental (« EIE ») le 19 novembre 2019, qui a fait l’objet d’un examen approfondi par le MELCC.  Troilus s’est également engagée dans des consultations communautaires avec les familles touchées sur la propriété de Troilus et les collectivités locales...

Continue reading

Precision BioSciences Receives Fast Track Disease Designation from U.S. Food and Drug Administration for PBCAR0191 Investigational Allogeneic CAR T Cell Therapy

DURHAM, N.C., Aug. 19, 2020 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Precision for PBCAR0191, the company’s lead investigational allogeneic chimeric antigen receptor (CAR T) cell therapy for the treatment of advanced B-cell precursor acute lymphoblastic leukemia (B-ALL).“Fast Track Designation is intended to fill an unmet medical need by accelerating the development of agents for patients in need of potentially better therapeutic options,” said Chris Heery, MD, Chief Medical Officer of Precision BioSciences. “We continue to work toward demonstrating that PBCAR0191, as well as our other...

Continue reading

Momenta Enters Definitive Agreement with Johnson & Johnson

Johnson & Johnson to acquire Momenta for $52.50 per share in cash, representing a total equity value of $6.5 billion and a 70% premium to Momenta’s closing price on August 18, 2020Momenta’s FcRn inhibitor, nipocalimab, has the potential to transform treatment of autoantibody-driven autoimmune diseasesTransaction expected to be completed in the second half of 2020CAMBRIDGE, Mass., Aug. 19, 2020 (GLOBE NEWSWIRE) — Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases announced today that it has entered into a definitive agreement for Johnson & Johnson (“Johnson & Johnson” or “J&J”) to acquire Momenta for $52.50 per share in an all-cash transaction, implying a fully-diluted...

Continue reading

Diabetes Drugs Market to Expand at 6.1% CAGR to Reach US$ 78,261.7 Mn by 2026 | Global Market Size, Share, Analysis, Forecast [2019-2026]

Pune, Aug. 19, 2020 (GLOBE NEWSWIRE) — The global diabetes drugs market derives growth from advancements in drug delivery systems. According to a report published by Fortune Business Insights, titled “Diabetes Drugs: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 48,753.1 Mn in 2018. Fortune Business Insights has predicted that the market will be valued at US$ 78,261.7 Mn by the end of 2026, thereby exhibiting a CAGR of 6.1%.The other highlights of the report include:•              Targeted analysis of the impact of COVID-19 on the market;•              Detailed study of the factors, trends, and constraints shaping the market;•              Careful evaluation of the regional dynamics influencing the market; and•              Thorough profiling and examination of the key market players and...

Continue reading

Netcompany – Decisions of Extraordinary General Meeting and new members of Audit Committee

Company announcementNo. 16/202019 August 2020Decisions of Extraordinary General Meeting and new members of Audit CommitteeToday, at 09:00 CEST, Netcompany Group A/S (“Netcompany”) held an Extraordinary General Meeting at the Company’s headquarters, Grønningen 17, DK-1270 Central Copenhagen, Denmark. At the Extraordinary General Meeting, the following was approved:Election of Hege Skryseth and Åsa Riisberg as new members of the Board of Directors.The amended Articles of Association.As previously informed, Robbert Kuppens has chosen to resign from the Board of Directors in connection with the Extraordinary General Meeting due to personal health issues. After the Extraordinary General Meeting, a board meeting was held to appoint members of the committees of the Board of Directors. Following the meeting, the Board of Directors is composed...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.